Many Health-Care Groups Laud Generics BillNearly 20 health-care organizations and PBMs come out in favor of FAST Generics Act. CVS Generic Drugs Suit Fails to Get Class ActionCalifornia judge blocks 11 classes in suit that claims CVS charged insurers and insured patients more than uninsured patients. $96.5 Million Generic Payout Latest Trouble for Mylan February 15, 2017By Christine BlankA $96.5 million settlement is the latest in a series of pricing and competition issues Mylan has faced in the past year. How New Biosimilars Will Impact the Market February 15, 2017By Christine BlankMore biosimilars are coming onto the market , including competitors for Remicade and Neulasta. CVS, Cigna on board with generic EpiPens January 19, 2017By Christine BlankThe urgent need for a less-expensive epinephrine auto-injector is now being addressed. Generics and biosimilars, key to Trump drug price concerns January 19, 2017By Christine BlankIf pharma is “getting away with murder” with drug pricing, more generic and biosimilars can help control costs, says this group. Issues about biosimilar substitution November 29, 2016By Christine BlankAt a time when biosimilars are of strong interest to insurers and health care systems for cost control, physicians are not rushing to issue a blank check for their substitution. Details here. Pharmacy prices vary widely for generic heart drugs November 29, 2016By Christine BlankThe prices of heart failure drugs at retail pharmacies vary widely, and uninsured patients may not be able to afford them, researchers have found.